Amgen is among the global top 10 pharmaceutical companies based on market value. As of August 2019, the company was worth some 115 billion U.S. dollars. Biopharmaceuticals manufactured by Amgen are also among the leading biotech drugs worldwide. Enbrel and Neulasta are the company’s flagship products, responsible for over one third of Amgen’s total revenue. Interestingly, Amgen generates almost three quarters of its revenues on the domestic U.S. market.
As is common in the biopharmaceutical industry, Amgen spends a significant proportion of its income on research and development. In 2019, Amgen spent nearly 18 percent of its revenue on R&D purposes. Some 26 percent of 4.12 billion dollars of R&D spending was for late-stage clinical programs, while the rest was for discovery research and for marketed products.